Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention
Study sponsor: AEON Biopharma, Inc. · AEON
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-07-31Actual
Enrollment · participants466Actual
Source updated2024-09-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.